Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen
Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen
Immatics終止與Bristol-Myers合作，共同開發針對黑色素瘤相關抗原的IMA401
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊